2nd International Meeting on Lung Cancer

Certifications are now available!
No available data. Please contact us via an email requesting your certification or call us to help you.

Welcome Address
A. Kotsakis (GR), N. Karachaliou (DE)

Chairs: G. Koukoulis (GR), N. Karachaliou (DE)
08.30-08.50 Microenvironment in NSCLC P. Foukas (GR)
08.50-09.10 Heterogeneity of NSCLC and tumor evolution C. Hiley (UK)
09.10-09.20 Q&A

Ο1-1 09.20 -09.35 AN INTERTWINED LYSOSOMAL GENE EXPRESSION AND FUNCTION MODULE DRIVEN BY TYPE I IFNS SHAPES CDCS1 IN TUMORS
E. Aerakis, D. Kerdidani, I. Angelidis, M. Matthaiakaki, S. Henri, M. Tsoumakidou

Ο1-2 09.35-09.50 HLA-CLASS-I EXPRESSION IS FREQUENTLY LOST IN NSCLC AND RELATES WITH
LOW CD8+ LYMPHOCYTIC INFILTRATION AND POOR POSTOPERATIVE PROGNOSIS
A. Giatromanolaki, I. M. Koukourakis, M. Kouroupi, M. I. Koukourakis

Ο1-3 09.50-10.05 THE ROLE OF PATIENT-DERIVED XENOGRAFTS IN INTRATUMOR HETEROGENEITY STUDIES
Z. Kanaki, A. Voutsina, A. Markou, I.S. Pateras, K. Potaris, M. Avgeris, P. Makrythanasis, E. Athanasiadis, I. Vamvakaris, E. Patsea, K. Vaclav, E. Lianidou, V. Georgoulias, A. Kotsakis, A. Klinakis

Chairs: A. Kotsakis (GR), D. Papadatos - Pastos (UK)
10.05-10.25 Challenges in Covid-19 era in the treatment of thoracic Tumors G. Geropoulos (UK)
10.25-10.30 Q&A

Chairs: P. Christopoulos (DE), F. Ι. Dimitrakopoulos (GR)
11.00-11.20 Rare EGFR mutations: How to treat? A. Georgiou (UK)
11.20-11.40 The future of TKIs in the adjuvant setting E. Karapanagiotou (UK)
11.40-12.00 Targeting resistance mechanisms to EGFR TKIs I. Mountzios (GR)
12.00-12.10 Q&A

Ο2-1 12.10-12.25 DETECTION OF EGFR MUTATIONS IN PLASMA cfDNA AND PAIRED CTCs OF NSCLC PATIENTS BEFORE AND AFTER OSIMERTINIB THERAPY USING CRYSTAL DIGITAL PCR
A. Ntzifa, A. Kotsakis, V. Georgoulias, E. Lianidou

O2-2 12.25-12.40 IDENTIFICATION OF PD-L1 AND pS6 EXPRESSION IN CIRCULATING TUMOR CELLS OF OSIMERTINIB-TREATED NON-SMALL-CELL LUNG CANCER PATIENTS
E. Pantazaka, Α. Ntzifa, E. Lianidou, A. Kotsakis, V. Georgoulia, G. Kallergi

Chairs: G. Oikonomopoulos (GR), E. Karapanagiotou (UK)
12.40-13.00 ALK positive lung cancer P. Christopoulos (DE)
13.00-13.20 KRAS mutant lung cancer: light at the end of the tunnel? F. Koinis (GR)
13.20-13.30 Q&A

Chairs: P. Christopoulos (DE), Ch. Charalambous (CY)
14.00-14.20 Diagnosis and treatment of MET-positive NSCLC N. Karachaliou (DE)
                     Sponsored by Merck
14.20-14.40 Diagnosis and treatment of ΗΕR2-positive NSCLC G. Nintos (UK)
14.40-15.00 Diagnostic workup and treatment of NTKR positive tumors M. Rovithi (GR)
15.00-15.20 The future of ADCs in advanced NSCLC K. Boleti (UK)
15.20-15.35 Q&A

Ο3-1 15.35-15.50 ACTIVITY OF OSIMETRINIB IN PRETREATED PATIENTS (pts) WITH EPIDERMAL RECEPTOR GROWTH FACTOR MUTANT (EGFRmt) NON-SMALL CELL LUNG CANCER (NSCLC), ACCORDING TO DETECTION OF CIRCULATING PLASMA DNA (ctDNA)
E. Kontopodis, G. Kallergi, A. Ntzifa, N. Jordana-Ariza, N. Karachaliou, E. Pantazaka,
Ch. Charalambous, A. Psyrri, A. Tsaroucha, I. Boukovinas, A. Koumarianou, D. Hatzidaki,
E. Lianidou, V. Georgoulias, R. Rosell, A. Kotsakis

Ο3-2 15.50-16.05 IS VIDEO-ASSISTED THORACOSCOPIC (VATS) SLEEVE LOBECTOMY A FEASIBLE ALTENATIVE TO OPEN SURGERY FOR CENTRALLY LOCATED NON-SMALL CELL LUNG CANCER?
I. Loufopoulos, G. Geropoulos, N. Madouros, K. Kapriniotis,
C. Kakos, Κ. Bhakhri, D. Papadatos - Pastos, N. Panagiotopoulos

Chairs: Κ. Boleti (UK), F. I. Dimitrakopoulos (GR)
16.30-16.50 Monitoring of minimal residual disease using ctDNA C. Abbosh (UK)
16.50-17.10 Monitoring of metastatic disease with ctDNA F. Papageorgiou (GR)
17.10-17.30 Liquid Biopsy Biomarkers in Lung Cancer E. Lianidou (GR)
17.30-17.40 Q&A

Ο4-1 17.40-17.55 EVALUATION OF MONOCARBOXYLATE TRANSPORTER 4 (MCT4) EXPRESSION AND
ITS PROGNOSTIC SIGNIFICANCE IN CIRCULATING TUMOR CELLS FROM PATIENTS WITH EARLY STAGE NON-SMALL-CELL LUNG CANCER
Α. Markou, E. Tzanikou, G. Kallergi, E. Pantazaka, V. Georgoulias, A. Kotsakis, E. Lianidou

Ο4-2 17.55-18.10 DNA METHYLATION ANALYSIS OF SELECTED TUMOR SUPPRESSOR GENES IN CIRCULATING TUMOR CELLS AND PAIRED PLASMA SAMPLES OF EARLY STAGE NSCLC PATIENTS
Τ. Lontra, V. Tserpeli, Α. Kotsakis, V. Georgoulias, Ε. Lianidou, Α. Markou

Chairs: D. Papachristou (GR), A. Klinakis (GR)
18.10-18.35 Molecular Pathology of Lung Cancer K. Linos (US)
18.35-18.40 Q&A
18.40-19.05 Incorporating functional genomics in the treatment of NSCLC G. Vasmatzis (US)
19.05-19.10 Q&A
19.10-19.35 New therapies in 1L metastatic NSCLC: how confident we are? G. Fotopoulos (CY)
                      Sponsored by Bristol Myers Squibb
19.35-19.45 Q&A

Chairs: M. Tsoumakidou (GR), Κ. Κosmatopoulos (FR)
08.45-09.05 TILs as a valid biomarker for immunotherapy I. Pateras (GR)
09.05-09.25 Immunology of new targeted therapies and immune checkpoint inhibitors P. Verginis (GR)
09.25-09.45 Novel approaches in Clinical practice D. Papadatos - Pastos (UK)
09.45-09.55 Q&A

Ο5-1 09.55-10.05 T-CELL RECEPTOR REPERTOIRE PROFILING OF METASTATIC NON-SMALL-CELL LUNG CANCER WITH HIGH PD-L1 EXPRESSION
M. Elshiaty, F. Lusky, H. Sültmann, A. Stenzinger, M. Thomas, P. Christopoulos

O5-2 10.05-10.20 CLINICAL ACTIVITY OF AN hTERT-SPECIFIC CANCER VACCINE (Vx-001) IN
“IMMUNE DESERT” NSCLC
I. S. Pateras, A. Kotsakis, M. Avgeris, E. Baliou, P. Kouroupakis, E. Patsea, V. Georgoulias,
J. Menez-Jamet, J-P. Kinet, K. Kosmatopoulos

O5-3 10.20-10.35 A CROSS-TALK BETWEEN CANCER ASSOCIATED FIBROBLASTS (CAFs) AND
T REGULATORY CELLS (Tregs) PROMOTES SUPPRESSION OF THE ANTI-TUMOR IMMUNITY AND BOLSTERS TUMOR DEVELOPMENT
A. Varveri, M. Papadopoulou, A. Delis, P. Foukas, P. Verginis

Chairs: V. Georgoulias (GR), K. Belessiotis (UK)
11.00-11.20 The perspectives of immunotherapy in the curative setting N. Pistamaltzian (GR)
                    Sponsored by Roche
11.20-11.40 Update of immunotherapy for advanced oncogene driven NSCLC D. Papadatos - Pastos (UK)
11.40-12.00 Update of immunotherapy for advanced non-oncogene driven NSCLC G. Oikonomopoulos (GR)
12.00-12.10 Q&A

O6-1 12.10-12.25 ULTRA-HYPOFRACTIONATED RE-IRRADIATION WITH anti-PD-1 IMMUNOTHERAPY FOR STAGE III RECURRENT NON-SMALL CELL LUNG CARCINOMA (NSCLC)
I. M. Koukourakis, A. Giaktzidis, P. Mamalis, A. Giatromanolaki, M. I. Koukourakis

O6-2 12.25-12.40 HYPOXIA ENHANCES PD-L1 AND CD47 IMMUNE CHECKPOINT MOLECULES IN
LUNG CANCER CELL-LINES
A. Mitrakas, A. Giatromanolaki, M. I. Koukourakis

Chairs: N. Pistamaltzian (GR), S. Baka (GR)
12.40-13.00 Immunotherapy in special populations D. Ziogas (GR)
13.00-13.20 Therapeutic options after immunotherapy failure Ch. Charalambous (CY)
13.20-13.30 Q&A

Chairs: M. Koukourakis (GR), G. Ioannidis (CY)
14.00-14.20 Molecular profiling in SCLC F. I. Dimitrakopoulos (GR)
14.20-14.40 Immunotherapy treatment in SCLC: Meeting the expectations V. Sarris (GR)
                       Sponsored by Astra Zeneca
14.40-15.00 New targets and future directions in SCLC K. Leventakos (USA)
15.00-15.10 Q&A

Chairs: Μ. Rovithi (GR), G. Fotopoulos (CY)
15.10-15.30 Molecular Biomarkers in Mesothelioma D. Oluf Roe (NOR)
15.30-15.50 The emerging therapeutic landscape in mesothelioma I. Metaxas (SUI)
15.50-16.10 Implementation of targeted therapies and immunotherapy in the treatment
of thymic malignancies S. Gennatas (UK)
16.10-16.20 Q&A

Chairs: A. Giatromanolaki (GR), N. Karachaliou (DE)
17.00-17.30 Molecular Landscape of Response to Immune Checkpoint Blockade in Lung Cancer:
Nuances, Challenges and Clinical Utility V. Anagnostou (USA)
17.30-18.00 KRAS and Immunotherapy F. Skoulidis (USA)

Chairs: T. Diamantopoulos (UK), M. Koukourakis (GR), D. Papadatos - Pastos (UK),
N. Panagiotopoulos (UK), A. Giatromanolaki (GR)
18.00-18.10 Patient with stage III NSCLC K. Belessiotis (UK)
18.10-18.20 Discussion Tumor Board
18.20-18.30 Patient with oligo-metastatic NSCLC Α. Kokkalis (GR)
18.30-18.40 Discussion Tumor Board
18.40-18.50 Patient with oligo-progressive NSCLC A. Markou (GR)
18.50-19.00 Discussion Tumor Board

Chairs: P. Kosmidis (GR), Α. Κοtsakis (GR)
Immunotherapy with bispecific antibodies N. Karachaliou (DE)

Abbosh C.
Lung Cancer Centre of Excellence, Univ ersity College London, London, UK
Aerakis E.
MSc, PhD Candidate, Physiology Laboratory, N.K.U.A - Institute of Bioinnovation BSRC “Alexander Fleming”, Athens, Greece
Anagnostou V.
MD, PhD, Assistant Professor, Medical Oncology, Director, Thoracic Oncology Biorepository, Upper Aerodigestive Oncology Program, Co-leader, Molecular Tumor Board, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, U.S.A
Baka S.
MD, MSc, PhD, Medical Oncologist, Interbalcan Hospital, Thessa loniki, Greece
Belessiotis K.
Clinical Oncologist, University College London Hospital, UK
Boleti K.
MD, PhD, FRCP, Consultant Medical Oncologist, Department of Oncology, Royal Free London NHS Foundation Trust, London, UK
Charalambous C.
BM (Soton) MRCP(UK) FRCR (UK), Consultant Clinical Oncologist, Bank of Cyprus Oncology Centre, Nicosia, Cyprus
Christopoulos P.
MD, PhD, Hematologist - Medical Oncologist, Thor ax klinik and National Center for Tumor Diseases, Heidelberg Univ ersity Hospital, Germany
Diamantopoulos A.
MD, PhD, FRCR, EBIR, FCIRSE Consultant Interventional Radiologist, Senior Lecturer (Hon), Clinical Lead for Interventional Radiology, Guy’s and St Thomas ’ NHS Foundation T rust & Kings College London, UK
Dimitrakopoulos F.I.
MD, PhD, Medical Oncologist, Division of Oncology & Molecular O ncology Laboratory, Department of Medicine, Univ ersity of Patras, Greece
Elshiaty M.
Thoraxklinik at Heidelberg University Hospital, NCT and TLCR at Heidelberg University Hospital, member of the German Center for Lung Research (DZL), Heidelberg, Ger many
Fotοpoulos G.
MD, PhD, FSMB (USA), Medical Oncology Consultant, UT Health San Antonio MD Anderson Alumni, Bank of Cyprus Oncology Center, Cyprus
Foukas P.
Gennatas S.
Consultant Medical Oncologist, Guy’ s and St. Thomas ’ NHS Foundation T rust, London, UK
Georgiou A.
Medical Oncologist, Guy’s and St Thomas ’ NHS Foundation T rust, London, UK
Georgoulias V.
MD, Emeritus Professor of Medical Oncology, School of Medicine, Univ ersity of Crete, Greece
Giatromanolaki A.
MD, Professor - Head, Department of Pathology, Medical School, Democritus University of Thrace, Greece
Hiley C.
Consultant Medical Oncologist, Univ ersity College London Hospitals, NHS Foundation T rust, London, UK
Ioannidis G.
Medical Oncologist, Deputy Director of the Oncology Department of Nicosia General Hospital, Cyprus
Kallergi G.
Assistant Professor of Biochemistry, Department of Biology, University of Patras, Greece
Kanaki Z.
Staff Research Scientist - Assistant Professor Level, Genetically Engineered Animal Model Laboratory, Basic Research Biomedical Research Foundation of the Academy of Athens, Greece
Karachaliou N.
MD, PhD, Medical Director, Global Clinical Development, Merck KGaA, Darmstadt, Germany
Karapanagiotou E.
Consultant Medical Oncologist, Guy’s and St. Thomas ’ NHS Foundation T rust, London, UK
Klinakis A.
PhD, Director of Research - Professor lev el, Biomedical Research Foundation of the Academy of Athens, Greece
Koinis F.
MD, PhD, Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Kokkalis A.
Resident In Medical Oncology, MSc, PhD Candidate, Univ ersity Hospital of Lar issa, Greece
Kontopodis E.
MD, Medical Oncologist, Attending Physician, Venizeleion General Hospital of Heraklion, Greece
Kosmatopoulos K.
Chief Executive Officer, Vaxon Biotech, Paris, France
Kosmidis P.
Head, Medical Oncologist, 2 nd Medical Oncology Department, Hy geia Hospital
Kotsakis A.
MD, PhD, Associate Professor of Medical Oncology, School of Medicine, University of Thessaly, Director of the Department of Medical Oncology, Gener al University Hospital of Larissa, Larissa
Koukoulis G.
Professor of Pathology, Department of P athology, University of Thessaly, Greece
Koukourakis M.
1st Department of Radiology, Radiotherapy Unit, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, Greece
Leventakos K.
MD, PhD, Assistant Professor, Chest ONCOLOGY and Clinical Studies Phase 1, Mayo Clinic, Rochester, USA
Lianidou E.
PhD, Professor of Analytical Chemistry - Clinical Chemistry, Analysis of Circulating Tumor Cells Lab, Department of Chemistry, University of Athens, Greece
Linos K.
MD, FCAP, FASDP, Associate Professor of Pathology, Geisel School of Medicine at Dartmouth, USA, Bone & Soft Tissue pathology and Dermatopathology Division, Director of Bone & Soft Tissue Pathology Division, Dartmouth Hitchcock Medical Center, USA
Lontra T.
MSc, PhD Candidate, Lab of Analysis Circulating Tumor Cells (ACTC), Lab of Analytical Chemistry, Dept of Chemistry, University of Athens, Athens, Greece
Markou Α.
Assistant Professor, Lab of Analysis Circulating Tumor Cells (ACTC), Lab of Analytical Chemistry, Dept of Chemistry, University of Athens, Greece
Metaxas I.
MD, Senior Consultant Medical Oncology , Cantonal Hospital Muensterlingen, Switzerl and
Mitrakas A.
Department of Radiother apy and Oncology, Medical School, Democr itus University of Thrace, Greece
Mountzios I.
Consultant - Medical Oncologist, 2nd Oncology Department and Clinical Trials Unit, Henry Dunant Hospital, Oncolife Institute Founder, Athens, Greece
Ntzifa A.
MSc, Analysis of Circulating Tumor Cells Lab (ACTC Lab), Department of Chemistry, National and Kapodistrian University of Athens (NKUA), Athens
Oikonomopoulos G.
MSc, Consultant in Medical Oncology, 2nd Oncology Department, Metropolitan Hospital, Athens Greece
Oluf Roe D.
MD, PhD, Department of Clinical and Molecul ar Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Cancer Department, Levanger Hospital, Levanger, Norway
Panagiotopoulos N.
MD, PhD, Consultant Thoracic Surgeon, Honorary Clinical Associate Professor UCL, Thoracic Surgery Department, University College London Hospitals (UCLH), UK
Papachristou D.
MD, PhD, Consultant Histopathologist, Professor, Univ. of Patras, School of Medicine, Professor (Adj.), Dept. of Pathology, Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Director, Dept. of, Pathology,’’Olympion’’ General Clinic, Patras, GREECE, Vice President of the Hellenic Group of Sarcomas and Rare Cancers (EOSSO), Athens, Greece
Papadatos-Pastos D.
Μedical Oncologist, University College London Hospitals, UK
Papageorgiou F.
PhD, Biologist, Diagnostics Lead Oncology, AstraZeneca Greece
Pateras I.
Bsc, MD, PhD, Pathologist, Assistant Professor, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Pistamaltzian N.
MD, PhD, Medical Oncologist, Oncology Dpt MITERA Hospital, Athens, Greece
Rovithi M.
Medical Oncologist, Agios Nikolaos General Hospital, Crete, Greece
Sarris E.
MD, MSc, Medical Oncologist, Consultant 4 th Oncology Department, Metropolitan Hospital, Athens, Greece
Skoulidis F.
MD, PhD, Assistant Professor, Department of Thoracic and Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, USA
Tsoumakidou M.
MD, PhD, Researcher B - Institute of Bioinnovation, BSRC “Alexander Fleming”, Athens, Greece
Varveri A.
MSc, PhD Student, Labor atory of Immune R egulation and Tolerance, Center of Clinical, Exper imental Surgery & Translational Research, Biomedical Research Foundation Academy of Athens, Greece
Vasmatzis G.
Co-director of the Biomarker Discovery Laboratory, Mayo Clinic Center for Individualized Medicine, Full Consultant in the Department of Molecul ar Medicine, Member of the May o Clinic Cancer Center, Rochester, USA
Verginis P.
Associate Professor Immunology and Biochemistry, Medical School, University of Crete, Heraklion, Crete
Ziogas D.
MD, PhD, Academic Scholar in Medical Oncology, First Department of Internal Medicine, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details